Abstract library

344 results for "proliferation index".
#138 The use of F-18-FDG-PET for patients with neuroendocrine tumors
Introduction: Neoplastic tissue exhibits high glucose utilization, which can be imaged by 18F-Fluorodeoxyglucose-positron emission tomography (FDG-PET). Whether FDG-PET is useful for neuroendocrine (NE) tumors, however, is questionable, due to the slow growth rate often observed in these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: M.Sc. Tina Binderup
#182 Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunoexpression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Assessment of liver metastases biology features associated with cell proliferation and adhesion has a strong prognostic impact in patients with gastroenteropancreatic (GEP) neuroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD, PhD Vera V. Delektorskaya
#1911 Histological Differentiation Provides Useful, Additive and Independent Prognostic Information to Proliferation Index in G2 and G3 Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
Introduction: The WHO 2010 classification has provided a valuable tool to stratify NEN prognosis based on an objective measure, the proliferation index. However, morphology and, in particular, tumor differentiation, is emerging again as a relevant feature that should not be dismissed due to its important clinical implications.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: MD-PhD Paula Jimenez-Fonseca
#33 Survival of Neuroendocrine Tumour Patients in Newcastle NHS Foundation Trust
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of 2-2.4 per 100,000, which derive from the neurones and epithelial cells of the diffuse neuroendocrine system. Neuropeptide-secreting NETs may present with overt clinical symptoms including abdominal pain, flushing and diarrhoea, whereas non-functioning NETs may be asymptomatic or present with obstructive symptoms. In Newcastle NHS Foundation Trust, NET patients are managed with a multi-disciplinary approach, according to UK and European NET guidelines.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Hearn K, Teo L, Bernstone G, Johnson S, ...
#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors
Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Atsuko Kasajima
#331 Four-years Follow-up in a Case of Gastric Neuroendocrine Carcinoma
Introduction: Poorly differentiated neuroendocrine carcinoma has a poor prognosis, regardless of the primary site.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Catalina Poiana
#507 Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?
Introduction: The WHO classification 2010 for neuroendocrine tumors (NET) defines poorly differentiated neuroendocrine carcinomas (NEC) as grade 3 (G3) according to mitoses> 20/10 HPF and/or Ki-67>20%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Fritz-Line Vélayoudom-Céphise
#2276 Ki-67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors
Introduction: Despite evidence of different malignant potential, postoperative follow-up is similar for G1 and G2 pancreatic neuroendocrine tumors (panNET) and adjuvant treatment is currently not indicated.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: M.D. Cansu Genc
#70 The validity of Ki-67 as a prognostic indicator in patients with appendiceal carcinoid tumor
Introduction: Carcinoid tumors of the appendix are rare and often discovered incidentally through appendectomy. Most are clinically benign but may be associated with metastatic disease. Ki-67, a nuclear protein structurally associated with chromatin, is an excellent marker for measuring cell proliferation and it has been shown to correlate with the outcome in pancreatic and ileocecal carcinoids.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Eric Y Liu
Authors: Liu E, Telem D A, Hwang J, Warner R R P, ...
#2175 A Retrospective Analysis of 344 Cases with Neuroendocrine Neoplasms
Introduction: Ki-67 is a nuclear protein that is strictly associated with cellular proliferation,acting as a cellular marker for proliferation in clinical practice to determine the degree to which the tumor cells are duplicating. Ki-67 index strongly ties to the prognosis and provides guiding significance to clinical decisions.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Zheng Liu
Authors: Liu Z, Zhao H, Wu Y, Jiang L, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.